On the other hand, CD19 CAR T cells have been used in relapsed and high-risk CLL with overall response rate of 57% of 14 patients and persistent B cell aplasia in 100% of patients with complete remission (CR) and half of the patients with partial remission (86, 87). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.